beraprost + aspirin

**beraprost + aspirin** is a combination therapy consisting of beraprost sodium, an orally active prostacyclin analog, and aspirin, an antiplatelet agent. Beraprost sodium primarily acts as a prostacyclin receptor agonist, leading to vasodilation, inhibition of platelet aggregation, and prevention of vascular smooth muscle proliferation. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) within platelets, suppressing thromboxane A2 production and reducing platelet aggregation. The combination has been evaluated for the treatment of acute ischemic stroke, where it may improve neurological and renal function over aspirin monotherapy without increasing bleeding risk[1][2][3].

Other names

beraprost sodium + aspirin